Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600-Wild-Type Colorectal Cancer
- 1 June 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (6), 835-846
- https://doi.org/10.1158/1541-7786.mcr-19-1201
Abstract
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained signaling through the MAPK pathway to promote cell proliferation in the presence of EGFR inhibition. Targeting of MEK in combination with EGFR inhibition leads to synergistic antiproliferative activity. Human KRAS/NRAS/BRAFV600-wild-type colorectal cancer cell lines with NF1 mutations displayed reduced NF1 mRNA or protein expression and were resistant to EGFR blockade by gefitinib or cetuximab. Cooccurring loss-of-function mutations in PTEN were associated with resistance to dual EGFR/MEK inhibition but cotreatment with a PI3K inhibitor further suppressed proliferation. Loss of NF1 may be a useful biomarker to identify patients that are less likely to benefit from single-agent anti-EGFR therapy in colorectal cancer and may direct potential combination strategies. Implications: This study suggests that further clinical validation of NF1 status as predictor of response to anti-EGFR targeting antibodies in patients with colorectal cancer with KRAS/NRAS/BRAFV600-wild-type tumors is warranted.Keywords
Other Versions
Funding Information
- Cancer Research UK
- National Institute of Health
- NIHR
- Biomedical Research Centre
- Experimental Cancer Medicine Centre
- ECMC
- Institute of Cancer Research
- Royal Marsden NHS Foundation
- NIHR (RP-2016-07-028)
This publication has 34 references indexed in Scilit:
- Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung CancerCancer Discovery, 2014
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyThe Lancet Oncology, 2014
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal CancerScience Translational Medicine, 2014
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human CellsScience, 2014
- Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical ModelsClinical Cancer Research, 2012
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersJCI Insight, 2011
- Colorectal cancerThe Lancet, 2010
- Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With CetuximabJournal of Clinical Oncology, 2007
- The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiaeCell, 1990
- THE TOXICITY OF POISONS APPLIED JOINTLY1Annals of Applied Biology, 1939